Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Fsd Pharma Inc Cl B (NQ: HUGE )

0.0899 UNCHANGED
Last Price Updated: 4:00 PM EDT, Aug 14, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Fsd Pharma Inc Cl B

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Subsidiary Receives Official Approval to Move Forward with Phase 1 Clinical Trial
Via Investor Brand Network
FSD Pharma Announces Its Australian Entity Receives Approval to Proceed With Phase 1 Clinical Trial of Lucid-201, a Candidate for the Potential Treatment of Major Depressive Disorder
From FSD Pharma Inc.
Via Business Wire
Psyched: 22 States With Reform Bills, Ketamine Therapy Services Today, Oscars On Shrooms & More
Psychedelics Reform Update: 22 States Where Proposals Are Being Discussed & Local Moves Considered 
Via Benzinga
Psychedelics Company Conducts Investigation Into Potential Naked Short Selling Of Its Stock
FSD Pharma Inc. (NASDAQ: HUGE) has renewed a service agreement with shareholder intelligence services provider ShareIntel LLC to assist in ongoing 
Via Benzinga
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Engages ShareIntel to Investigate Possible Naked Short Selling of Its Stock
Via Investor Brand Network
FSD Pharma (Symbol: HUGE) Renews Shareholder Intelligence Services to Investigate Possible Naked Short Selling and Appeals to The Regulators and Oversight Bodies to Look Into The Short Selling Activity Of Its Stock
From FSD Pharma Inc.
Via Business Wire
Benzinga's Psychedelics Capital Conference: Meet An Unrivaled Group Of Advisors And Fund Partners
The upcoming Psychedelics Capital Conference constitutes Benzinga’s effort to provide an exclusive opportunity to meet, connect with and learn from some of the most knowledgeable people in the space. 
Via Benzinga
Psyched: 9 US Reform Bills, Ayahuasca 'A Release' For Prince Harry, At-Home Therapy & More
Psychedelics Bills Around The Country: 9 New Proposals, Several Passes, Several Fails And A Successful Local Decriminalization Throughout the 2023 session, numerous discussions have been... 
Via Benzinga
Here Are The Year's Highest Priced Psychedelics Stocks In US Markets
After everything that's happened in the last several years, we believe it's safe to say that the psychedelic renaissance is a reality, one that Benzinga has consistently reported on.   
Via Benzinga
BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) News Discussed in Latest InvestmentPitch Media Video
Via Investor Brand Network
Shark Tank's Kevin Harrington Will Provide Strategic Guidance To Major Psychedelics Company
Psychedelics biopharma company FSD Pharma Inc. (NASDAQ: HUGE)’s advisory board has a new member: the iconic entrepreneur and inventor of the infomercial Kevin Harrington. 
Via Benzinga
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Expands Advisory Board to Welcome Original ‘Shark’ and Visionary Kevin Harrington
Via Investor Brand Network
Original “Shark” and Iconic Entrepreneur Kevin Harrington Joins FSD Pharma Advisory Board
From FSD Pharma Inc.
Via Business Wire
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) to Interact with Leaders Pushing Boundaries of MS Research at Upcoming Forum
Via Investor Brand Network
FSD Pharma Presenting Two Scientific Posters on Preclinical Toxicology and Efficacy Data of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2023 Forum
From FSD Pharma Inc.
Via Business Wire
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Receives Confirmation of NASDAQ Compliance
Via Investor Brand Network
FSD Pharma Regains Compliance with NASDAQ Continued Listing Requirements
From FSD Pharma Inc.
Via Business Wire
Psychedelics For Alcohol Use Disorder: Awakn Opens European Clinic, FSD Launches R&D Program
Awakn Opens Fourth European Clinic, Norway Takes Center Stage 
Via Benzinga
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Launches New Program Targeting Unmet Medical Needs for Alcohol Misuse
Via Investor Brand Network
FSD Pharma Launches A New Research and Development Program Targeting Unmet Medical Needs for Alcohol Misuse
From FSD Pharma Inc.
Via Business Wire
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Receipt of No Objection Letter from Health Canada Is Focus of Recent InvestmentPitch Media Video
Via Investor Brand Network
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Receives Health Canada Regulatory Approval to Move Forward with Phase 1 Trial
Via Investor Brand Network
FSD Pharma Receives Regulatory Clearance for Its Proposed Phase-1 Clinical Trial of Lucid-21-302 (Lucid-MS), First-in-Class Multiple Sclerosis Drug Candidate
From FSD Pharma Inc.
Via Business Wire
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Commences Recruitment in FSD201 Phase 2 Clinical Trial
Via Investor Brand Network
Exposures Product Safety
Recruiting Underway in FSD Pharma’s Phase 2 Trial of FSD-PEA (FSD201) for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD)
From FSD Pharma Inc.
Via Business Wire
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Spotlighted in InvestmentPitch Media Video Discussing Clinical Trial Application
Via Investor Brand Network
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Submits Phase-1 Clinical Trial Application for Lucid-MS
Via Investor Brand Network
FSD Pharma submits its phase-1 Clinical Trial Application for Lucid-MS (Lucid-21-302) for first-in-human safety and tolerability investigation
From FSD Pharma Inc.
Via Business Wire
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Board Authorized Share Repurchase Program
Via Investor Brand Network
FSD Pharma Announces Share Repurchase Program
From FSD Pharma Inc.
Via Business Wire
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.